Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

Memantine Repurposing for NMDA-mediated Excitotoxicity

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19832563

Memantine Repurposing for NMDA-mediated Excitotoxicity

Abstract

Memantine's uncompetitive NMDA receptor antagonism provides neuroprotection against excitotoxicity resulting from GABAergic dysfunction in SSADH deficiency. The drug's voltage-dependent blocking mechanism preserves physiological NMDA signaling while preventing pathological calcium influx during seizure activity and metabolic stress.

Powered by OpenAIRE graph
Found an issue? Give us feedback